

## Inhaled Corticosteroids Its Evolution and Step Wise Pharmacological Treatment Strategies for All Levels of Asthma: A Review

Shaili Dongare<sup>1</sup>, Karishma Rath<sup>1,\*</sup> & Gulshan Rath<sup>2</sup>

<sup>1</sup>Pharm D Intern of the Department of Pharmacy Practice at Dr. D.Y. Patil Institute of Pharmaceutical Sciences and Research Pimpri, Pune, India. <sup>2</sup>Department of Pharmaceutics at V.S.S Institute of Pharmacy, Badnapur, India

\*Corresponding author: Karishma.rathi@dypvp.edu.in

Received: (12/2/2024), Accepted: (12/4/2024), Published: (1/12/2024). DOI:

<https://doi.org/10.59049/2790-0231.1282>

### ABSTRACT

Asthma, characterized by respiratory symptoms and airflow restriction, requires a stepwise treatment approach for symptom reduction and exacerbation prevention. The Global Initiative for Asthma (GINA) aims to globally prevent, manage, raises awareness of asthma and providing yearly resources for healthcare providers. The 2023 GINA report provides practical pharmacological advice, including key changes in GINA strategy, recommended Inhaled Corticosteroid (ICS) dosages for different age groups. It explores the pathophysiology, historical evolution of asthma treatment, from smoke inhalation to modern inhalers, emphasizing cost and availability issues in low to middle-income countries like Nepal, Peru, and Uganda. Furthermore, the review emphasizes the role of pharmacogenomics in customizing asthma treatment based on individual genetic variations. Addressing potential side effects of ICS use, it proposes management strategies to minimize risks. This comprehensive approach aims to improve asthma control, reduce exacerbations, and enhance patient outcomes globally, while acknowledging the challenges faced in resource limited settings. Integration of pharmacogenomic data with clinical information enables tailored therapeutic strategies, advancing precision medicine in asthma care and improving patient quality of life. The review also highlights the issue of delayed specialist referrals for challenging asthma cases and offers revised guidelines for stepwise approaches to treatment across severity levels. It underscores the need for special considerations in low to middle-income countries due to limited access to inhaled medications. Overall, the review advocates a holistic approach to asthma management, combining pharmacology with genetic insights and improved healthcare delivery, to address the complexities of asthma care worldwide.

**Keywords:** Global Initiative for Asthma (GINA), Inhaled corticosteroids (ICS), Anti-inflammatory, Asthma, COPD.

### INTRODUCTION

Asthma, a type of obstructive airway disease, was first described in ancient Greek as "noisy breathing." Asthma is a long-term respiratory condition that impacts individuals globally. As of May 4<sup>th</sup> 2023, the most recent report from the World Health Organization (WHO) states that around 262 million individuals globally suffered from asthma in 2019, resulting in 455,000 deaths. This is because of the fundamental pathophysiology involving persistent inflammation in the airways [1]. When not effectively controlled, this inflammation results in a progressive reduction in lung function over time. Repeated episodes of airway inflammation give rise to a range of symptoms including coughing,

tightness in the chest, wheezing and tightness in the chest. These symptoms change in both duration and severity, and are accompanied by varying degrees of expiratory airflow restriction, leading to considerable rates of death and illness [2].

The Global Initiative for Asthma (GINA) was established in 1993 with the collaboration of WHO and the US National Heart Lung and Blood Institute to improve worldwide understanding, prevention, and treatment of asthma [3]. The GINA guidelines serve as a comprehensive, evidence-based strategy for asthma management and prevention, annually updated to reflect the latest best practices in the field. These guidelines aim to provide clinicians with practical guidance on confirming asthma diagnosis, personalized

asthma management, and regular assessment of modifiable risk factors to optimize asthma outcomes. While GINA guidelines offer a global perspective, it is crucial to adapt these recommendations to suit local healthcare systems, considering factors such as healthcare infrastructure, resource availability, cultural considerations, and socioeconomic factors that may influence their implementation in diverse regions. By aligning with GINA guidelines, healthcare providers can benefit from improved asthma outcomes, standardized care practices, and enhanced collaboration among healthcare professionals. However, challenges related to accessibility, affordability, acceptability, and sustainability of asthma care interventions must be addressed when implementing GINA guidelines in different healthcare settings [3-4]

Key changes in the GINA strategy report relevant to clinical practice include: 1) Expanded indications for starting regular controller treatment: The GINA report now includes a new table with evidence-based recommendations for initiating controller treatment, such as earlier initiation of low-dose inhaled corticosteroids for patients with symptoms twice or more a month and/or risk factors for exacerbations. 2) Tailoring asthma treatment for individual patients: The GINA report describes a framework for personalized asthma management, considering factors such as symptom control, risk factors, lung function, and patient preference. 3) Assessment of asthma control: The GINA report emphasizes the importance of assessing asthma control from two domains: symptom control and risk factors, and no longer includes lung function as a measure of symptom control. 4) Asthma severity: The report clarifies that asthma severity is a retrospective label, assessed from treatment needed to control asthma. 5) Practical tools and clinical algorithms: The GINA report provides practical tools and clinical algorithms to help clinicians distinguish between uncontrolled and severe refractory asthma. These updates aim to improve the implementation of evidence-based recommendations in clinical practice, ultimately leading to better asthma control and reduced risk of exacerbations [2,4-6].

A systematic search strategy was employed to gather relevant research on asthma management. Electronic databases like PubMed, Google Scholar and MEDLINE were searched for publications addressing asthma management. Keywords and Medical Subject Headings terms related to the topic were used. Studies were selected based on pre-defined criteria (e.g., study design, population). Software tools might have been used for initial screening and duplicate removal. Data extraction focused on key findings and details from the GINA 2023 report. A narrative synthesis approach will likely be used to summarize and interpret the findings. This review article explores current asthma management, tracing its evolution from historical practices to modern inhalers. It examines the 2023 GINA report's emphasis on personalized medicine, including tailoring treatment based on symptoms, risk factors, and pharmacogenomics. By integrating pharmacology, these advancements, and improved healthcare delivery, the review highlights the potential for better global asthma control and patient outcomes, while acknowledging challenges in resource-limited settings.

### **Brief History of Asthma Treatment**

Asthma is derived from the Greek word meaning "short ness of breath," which indicated that every patient suffering dyspnoea had asthma. The historical progression of asthma management has evolved significantly over time, from ancient remedies like smoke inhalation to the development of modern inhalers and advanced therapies. In ancient times, various treatments were attempted, such as drinking wine or inhaling smoke from burning jimson weed [9]. In the latter half of the 1800s, Henry Hyde Salter's treatise "On Asthma and its Treatment" was published, which helped to refine the word. In this research, Salter provided a definition for asthma that captures his idea of the disease: "Paroxysmal dyspnoea of a peculiar character with intervals of healthy respiration during attacks." The disease causes the airways to narrow as a result of smooth muscle tension [7]. Approximately thirty years prior to Paul Ehrlich established aniline stains for mast cells and eosinophils, remarkably depicted

airway conditions in asthma and bronchitis. He also mentioned black coffee, containing theophylline derivatives, as a treatment for asthma symptoms. [7- 8] The doctor needed to first rule out infectious illnesses or internal organ conditions like mitral stenosis, both common during that era. Once confirming a respiratory disorder, treatment options were unfortunately quite limited at the time. Inhaling smoke from burning jimson weed was probably the most straightforward remedy, as it was commonly used at the time. This drug was the precursor of the antimuscarinic drugs that are today prescribed, such as ipratropium and tiotropium, and it possessed anticholinergic properties [9]. There have been a number of different treatments, such as breathing in hydrocyanic acid fumes or using a bellows inflating the lungs. Fortunately, these kinds of treatments along with many more that were not profitable and likely caused harm, are no longer being utilized [10].

Sir William Osler in 19th century described asthma as a disease characterized by bronchial spasms and identified triggers like climate, emotion, and diet. As per Osler's 1914 eighth edition of *Principles and Practise of Medicine*, hypodermic injections of alkaloids are an effective treatment for bronchial asthma. He goes on to say that antispasmodics with sedative properties, like belladonna, "may be administered in the form of cigarettes" [7]. In 1914, common asthma treatments like lozenges and cigarettes contained plants from the potato family, with effectiveness varying among patients. Anticholinergics, either injected or inhaled, were considered mainstays for asthma treatment. Osler noted individual responses to treatments, reflecting modern understanding of genetic variances contributing to adverse reactions.

Atropine, belladonna, and stramonium leaf smoke are also suggested by Francis Rackemann in Cecil's *A Textbook of Drugs*, published in 1927. This suggestion persists in the seventh edition of Cecil's *A Textbook of Drugs*, released in 1947 [10], wherein Rackemann continues to support the use of alkaloids of the belladonna type in powder form for respiratory conditions or in cigarettes for asthma. But as J.B.L. Howell pointed out

when he excluded belladonna alkaloids from the regular edition of the textbook in 1975, they were no longer regarded as a major part of treating asthma [10]. Between 1928 and 2012, our understanding of respiratory diseases underwent three significant transformations. First, spirometry, developed in the preceding decade, was refined by incorporating time and volume data, enabling the use of forced exhalation measurements in diagnosing and treating respiratory diseases from the late 1940s to early 1950s. Fourteen different lung-function tests were developed, shedding light on the connections between symptoms and clinical physiology. The relation between clinical physiology and symptoms were clarified by the development of fourteen different lung-function tests. Second, glucocorticoids were recognized as effective treatments for respiratory illnesses. They were first used to improve patient care systemically in the early 1950s. Later, inhaled versions of them became available, further improving patient care even now. Third, our comprehension of the immunobiology of respiratory diseases improved. It was revealed that the primary mechanism involved immediate hypersensitivity reactions. Despite advancements in understanding respiratory disease cell biology, these discoveries have not yet resulted in new treatments, although some new therapies have been developed based on our improved understanding of immediate hypersensitivity reactions, including the use of anti-IgE antibodies and leukotriene modifiers [11-12].

Recent advancements focus on identifying genetic factors contributing to asthma and developing targeted therapies based on improved understanding of immune reactions. This historical context underscores the significant advancements in managing asthma, transitioning from symptomatic relief to targeted inflammation control and personalized treatment approaches [8,13].

Some of the most significant advancements in asthma treatment in the past decade include the introduction of biologics for severe asthma management. Biologics, such as omalizumab, have revolutionized severe asthma treatment by targeting specific immune system components like IgE to reduce airway inflammation. Additionally,

triple-drug therapy, combining corticosteroids and long-acting beta-agonists with a third medication, has shown promising results in managing severe asthma. The use of connected technologies and inhaler-based medicines has improved patient access and outcomes, while advancements in personalized treatment approaches and the development of new drugs have enhanced the overall landscape of asthma management. These innovations have led to real and

measurable improvements in patient care, marking an exciting era in asthma research and treatment [14,15].

### *Levels of asthma*

Asthma severity is categorized into four levels depending on its intensity. The severity of asthma levels according to GINA classification by clinical features prior to treatment is displayed in the following table. (See Table 1) [16-18].

**Table (1):** Severity of asthma levels according to GINA classification by clinical features prior to treatment.

<b>Asthma levels based on severity</b>	<b>Day Symptoms</b>	<b>Symptoms at night</b>	<b>FEV1 or PEF</b>	<b>PEF variability</b>
Intermittent	< 2 Time a week, and normal PEF in between attacks	<2 times a month	80 %	<20%
Mild Persistent	> 3 time a week but < 1 time a day	1 time per week	≥ 80%	20-30%
Moderate Persistent	Daily attacks impact on activity.	>1 time a week	60%-80%	> 30%
Severe Persistent	Ongoing restricted physical movement	Frequent	≤ 60%	> 30%

FEV1: forced expiratory volume in one second, PEF: peak expiratory flow rate.

Having asthma requires understanding both your airway condition and the typical symptoms associated with the condition. Familiarity with these symptoms is crucial for identifying triggers, determining when immediate relief medications are necessary, and recognizing situations that require urgent medical attention.

Asthma leads to three specific changes in your airways (see figure 1):

1. Inflammation of the respiratory tract.
2. A build-up of mucus obstructs the airways.
3. The muscles surrounding the airways contract and tighten.

The inflammation, muscle constriction and congestion cause your airways to become narrower. This obstruction makes it challenging for air to flow freely through your respiratory passages, making breathing more difficult [17]. This results in the symptoms of asthma, also known as asthma episode or attack, which can occur unexpectedly. While more severe asthma symptoms or attack may start hours or days later, milder symptoms may just last a few minutes. Breathing feels

tough and uncomfortable, like trying to breathe through a straw filled with cotton [18].

### *Pathophysiology of asthma*

Asthma is a long-term lung problem where the airways get swollen, making them overly sensitive and causing difficulty breathing. This condition involves a mix of chronic inflammation, increased sensitivity of the air passages, and reduced airflow. How these factors work together affects how severe the asthma symptoms are and how well treatment works (See figure 1 pathophysiology of asthma) [19].

### *Airway Inflammation*

#### *The acute stage of inflammation*

In individuals prone to allergies, when they breathe in allergens, such as pollen or dust, these substances get trapped in the mucus lining of their airways. Antigen-presenting cells, particularly dendritic cells, then pick up these allergens. Following this, dendritic cells present the allergens to naive CD4+ T cells. The way these cells interact determines whether the naive CD4+ T cells will transform into T-helper type 1 (Th1) or T-helper type 2 (Th2) cells. In people with

allergic asthma, there tends to be a prevalent Th2 response, which promotes the development of allergic inflammation in the airways [14]. The presence of high-affinity IgE receptors on mast cells triggers a process known as degranulation, leading to the release of pre-synthesized mediators. This release subsequently induces bronchoconstriction, airway swelling, and damage to nearby tissues [19].

#### ***The late stage of inflammation.***

During the later stage of inflammation, chemicals released by mast cells attract eosinophils, basophils, neutrophils, and lymphocytes, all playing a role in prolonging the inflammatory process. Eosinophils, in particular, emerge as the key and abundant inflammatory cells at this stage. Th2 cells produce IL-5, which amplifies eosinophil growth, development, and movement, leading to the release of harmful granular proteins, alongside additional cytokines and chemokines. Eosinophil activity results in tissue damage, excessive mucus production, heightened permeability of blood vessels, muscle tightening, and a persistent inflammatory response. This sets the stage for the recruitment of other cell types to the inflammation site, perpetuating the reaction [20].

#### ***Airway hyperresponsiveness***

Airway hyperresponsiveness refers to an exaggerated narrowing of the airways in response to various triggers. Factors like inflammation, nervous system dysfunction, and structural alterations contribute to this hyperresponsiveness, with inflammation being a significant determinant of its severity.


It's widely recognized that therapy involving ICS effectively reduces airway hyperresponsiveness in individuals with asthma [19].

#### ***Bronchoconstriction***

The narrowing of airways, stands as the primary physiological process driving clinical symptoms in asthma. Allergen-induced bronchoconstriction arises from IgE-triggered mast cell degranulation, releasing mediators like histamine, tryptase, leukotrienes, and prostaglandins. In some patients, aspirin and similar nonsteroidal anti-inflammatory drugs prompt mediator release and bronchoconstriction through a non-IgE-dependent mechanism. Additionally, stimuli such as exercise, cold air, and irritants can induce acute airflow obstruction in certain individuals [18].

#### ***Airway Remodelling***

Chronic airway inflammation in asthma can lead to airway remodelling, characterized by permanent changes such as thickening of the basement membrane, fibrosis, smooth muscle enlargement, blood vessel dilation, and increased mucous gland activity. This process, driven by complex interactions among various cell types, results in irreversible airflow limitation, persistent disease, progressive loss of lung function, and limited response to therapy. ICS target this inflammation by binding to glucocorticoid receptors, though corticosteroid resistance may occur in smoking asthmatics and severe cases due to decreased histone deacetylase-2 activity, impairing the ability to deactivate inflammatory genes effectively [19- 22].



**Figure (1):** Pathophysiology of asthma.

### Inhaled corticosteroids

In asthma treatment, inhaled corticosteroids (ICS), also called glucocorticosteroids, glucocorticoids, and steroids, are highly effective at calming inflammation in the airways, even in small doses [23].

ICS are the primary treatment for asthma management and exacerbations. They work by reducing inflammation in the airways, which helps prevent asthma symptoms and flare-ups. ICS are anti-inflammatory drugs that also modulate the immune response in the airways, leading to better asthma control and fewer symptoms. They are typically used in combination with other asthma medications, such as long-acting beta-agonists or leukotriene receptor antagonists, to provide comprehensive asthma management [24].

In the past decade, significant advancements in asthma treatment have been made, particularly in the use of ICS. The 2023 GINA strategy report recommends that all adults, adolescents, and most children with asthma should receive ICS-containing therapy to reduce the risk of asthma exacerbations and improve asthma control. The report also emphasizes the importance of personalized treatment approaches, considering factors such as age, severity of asthma, and treatment response [25]. For adults and adolescents with mild asthma, the preferred regimen is maintenance-and-reliever therapy (MART) with ICS-formoterol, while for patients with moderate-to-severe asthma, the recommended regimen is combination ICS-formoterol. The report also highlights the need for ongoing medication decisions based on the patient's needs within a track, using the same reliever. Additionally, the report stresses the importance of addressing modifiable risk factors and comorbidities, checking and correcting adherence and inhaler technique, and considering the use of biologic therapy based on the patient's inflammatory phenotype [24-26].

### *Mechanism of action of Inhaled Corticosteroid*

ICS molecules attach to glucocorticoid receptors (GR) in the cytoplasm after diffusing through the cell membranes of respiratory epithelial cells and other cells in

the airway [19]. The glucocorticoid-response elements (GRE) in the promoter region of steroid-sensitive genes, which may produce anti-inflammatory protein molecules, are bound by the steroid-receptor complex after it moves into the nucleus. Overall, there is an increase in the transcription of anti-inflammatory genes and a suppression of activated inflammatory genes. ICS lessen airway hyperresponsiveness and regulate asthma symptoms by suppressing airway inflammation. Many of the side effects of corticosteroids are caused by suppression of gene transcription. For example, osteocalcin is expressed in a manner that is inhibited by corticosteroids and plays a role in bone synthesis. In asthma treatment, it's thought that inhaled corticosteroids (ICS) increase the number of  $\beta_2$  receptors on cell membranes, while  $\beta_2$ -agonists may indirectly enhance the anti-inflammatory effects of ICS [19, 26-27].

In smoking asthmatics and severe asthma patients, corticosteroid effectiveness is relatively low, unlike those with chronic obstructive pulmonary disease (COPD), where corticosteroid response is generally poor. This is due to reduced activity and expression of histone deacetylase-2 (HDAC2) in these patient groups, which prevents corticosteroids from deactivating inflammatory genes [26]. Normally, activated glucocorticoid receptors (GR) recruit HDAC2, which reduces inflammation by modifying gene activity. However, oxidative stress from cigarette smoke and intense inflammation in severe asthma and COPD diminish HDAC2 activity, reducing the anti-inflammatory impact of corticosteroids [26, 28].

### *Anti-inflammatory effect of corticosteroid in asthma*

It reduces the inflammation by decreasing the eosinophil number and increasing the apoptosis of eosinophils [29]. It decreases the cytokine release from T lymphocytes, decreases the activity of mast cell numbers, and decreases the cytokine release from macrophages; it also decreases the dendritic cell numbers, which contain antigen. It has structural cells in the respiratory track, it decreases cytokine and other inflammatory mediators release from epithelial cells,



decreases plasma leak from the endothelial cells, decreases the cytokine and increases the beta 2 receptor numbers so broncho relaxation can occur, and it also decreases the mucus secretion from mucus glands [30].

### ***The use of corticosteroids hinders respiratory tolerance***

The ability of the respiratory system to tolerate innocuous antigens entering the lungs through inspired air is a very effective mechanism for reducing inflammation in the airways and limiting the immune system responses. In a study led by Philippe Stock and colleagues, it was observed that the use of dexamethasone hindered the enhancement of respiratory tolerance. This resulted in increased proliferation and cytokine secretion by antigen-specific T cells, along with airway hyperreactivity. Additionally, dexamethasone suppressed Interleukin (IL)-10 synthesis in dendritic cells (DCs) within the mice with tolerated lungs, diminishing their ability to transmit tolerance and promote the formation of antigen-specific regulatory T (TReg) cells. As a result, while corticosteroids may alleviate acute allergic inflammation, they might additionally obstruct the immune system's reaction known as respiratory tolerance from developing, which is essential for controlling T helper 2 (Th2) cell to allergic respiratory inflammation [31-33].


### **Beta-2 adrenergic agonists**

Beta-2 adrenergic agonists, such as salbutamol and formoterol, are widely used in asthma treatment due to their bronchodilatory effects. These agonists primarily act on airway smooth muscles by binding to beta-2 receptors, triggering a cascade of events leading to smooth muscle relaxation [34-35].

### ***Mechanism of action of Beta-2 adrenergic agonists***

Beta-2 adrenergic agonists work by relaxing airway muscles through the stimulation of specific receptors, leading to bronchodilation. The activation of beta-2 adrenergic receptors induces bronchodilation and relaxation of airway smooth muscles, crucial in enhancing airflow in individuals with asthma. By binding to these receptors, beta-agonists trigger a cascade of events that lead to the relaxation of the smooth muscle

cells lining the airways. This process involves an adrenergic receptors are linked to a stimulating G protein that triggers adenylyl cyclase (AC). This enzyme generates cAMP as a second messenger. In the lungs, cyclic adenosine monophosphate (cAMP) reduces calcium levels in cells and activates protein kinase A (PKA). These changes deactivate myosin light-chain kinase (MLCK) and activate myosin light-chain phosphatase (MLCP). On the other hand, muscarinic antagonists contribute to bronchodilation by blocking acetylcholine (ACh), a substance that typically triggers the contraction of airway smooth muscles. By inhibiting acetylcholine's (ACh) action at receptor sites, muscarinic antagonists indirectly prevent the tightening of airway muscles, promoting smooth muscle relaxation. Moreover, beta-agonists can also influence membrane K<sup>+</sup> channels, further promoting muscle relaxation without a significant rise in cAMP levels. These mechanisms collectively contribute to the improved airflow and relief of bronchoconstriction experienced by individuals with asthma. The Figure 2. Explains how bronchodilators work to relax smooth muscles in the airways. Beta-2 adrenergic receptor agonists not only directly relax muscles but can also reduce signals from the parasympathetic ganglia by activating specific receptors. This double action helps in overall muscle relaxation and bronchodilation, making breathing smoother [35-37]



**Figure (2):** Bronchodilators work to relax smooth muscles in the airways.

### **Step wise Pharmacological approaches to treating asthma at every level of severity**

GINA 2023 updated guidelines suggested the following steps focusing on risk reduction.

According to GINA, the main objectives of asthma treatment are to achieve the best possible asthma control and lowering the risk of flare-ups, mortality, reduction in lung functionality and negative side effects of medication [4].

**Step 1:** For adults and adolescents, Step 1 involves the use of low dose ICS-formoterol necessary for relief of symptoms (an anti-inflammatory medication), and patients with mild asthma, who have symptoms that occur less than twice a week and less than two night-time awakenings per month, are prescribed to use short-acting beta-2 adrenergic agonists (SABA) on an intermittent basis [4,40].

**Step 2:** In step 2, the typical dosage of budesonide-formoterol as needed for mild asthma is one inhalation of 200/6 mcg (or 160/4.5 mcg delivered dose), taken when symptoms are relieved. If as needed ICS-formoterol is unavailable and the patient is unlikely to take regular ICS, another option is to use SABA inhalers in combination or separate ICS inhalers [4,41].

**Step 3:** In Step 3 of asthma management, Maintenance and Reliever Therapy (MART) with low-dose budesonide-formoterol or beclomethasone-formoterol is recommended. The typical prescribed doses are 200/6 mcg for budesonide-formoterol and 100/6 mcg for beclomethasone-formoterol, taken as one inhalation twice daily for maintenance and as needed for symptom relief [4,42].

**Step 4:** In Step 4 of the GINA report, the MART regimen can be implemented by increasing the twice-daily maintenance dose to two inhalations of moderate-dose beclomethasone-formoterol or budesonide-formoterol. The reliever dose remains at 1 inhalation of low-dose ICS-formoterol as needed, with standard doses of 100/6 mcg for beclomethasone-formoterol and 200/6 mcg for budesonide-formoterol, both taken as two inhalations twice a day for maintenance and one inhalation when required for symptom relief [4,41].

**Step 5: Add on therapy:** Add-on therapy for severe asthma may include low-dose azithromycin, long-acting muscarinic antagonists (LAMA), high-dose ICS-LABA combinations, and biologic agents tailored to

the inflammatory phenotype and clinical features. Oral corticosteroids should be a last resort due to potential long-term side effects, with bisphosphonates recommended to prevent osteoporosis [4,43]. Omalizumab, an anti-IgE monoclonal antibody, can benefit individuals with atopic conditions by reducing steroid dependency and improving symptom management [44].

### **Step-down therapy**

Achieving and maintaining optimal asthma control for 2-3 months, along with reaching a stable level of lung function, often allows for successful reduction of treatment without compromising asthma management [4, 45]. To determine the least amount of treatment necessary for the patient, aiming to uphold effective control over symptoms and prevent exacerbations, while minimizing both the financial expenses and the potential side effects associated with the treatment [46]. To motivate the patient to keep receiving maintenance care, because they are worried about the expenses or risk associated with daily treatment, patients frequently experiment with intermittent treatment, which exposes them to the risks associated with SABA alone [45]. There is an alternative for patients whose asthma is well controlled on maintenance low-dose ICS with as-needed SABA, discontinuing maintenance ICS and switching to as-needed low-dose ICS-formoterol [46-47].

### **Before stepping down**

Each patient's step-down procedure for asthma treatment is vary and based on their preferences, risk factors, and present therapy [48]. Limited data are available regarding the most effective timing, order, and extent of reducing asthma treatment. Some factors that make it more likely for someone to have problems after reducing treatment include having had asthma attacks or emergency visits for asthma in the past year [49-50] and having a low baseline Forced Expiratory Volume 1 (FEV1) [51]. Other signs of losing control when reducing medication include airway hyper responsiveness and sputum eosinophilia [50]. Stepping down a regimen of treatment should always be viewed as a therapeutic trial, with response to treatment measured in terms of frequency of flare-ups as well as control of



symptoms. A handwritten asthma remedy strategy and recommendations on when to start their prior therapy should be given to the patient before they step down, in case their symptoms get worse [4, 52].

#### ***How to step down asthma treatment***

Determinations regarding the adjustment of treatment should be personalized for each patient. In a study involving individuals with adequately controlled asthma using a moderate dose of inhaled corticosteroid (ICS) and LABA. Cutting down on the ICS dosage and stopping the LABA had similar impacts on a combined therapy failure outcome. Nevertheless, ceasing the LABA was associated with worsening lung function along with increased hospital stays, and lowering the ICS dose proved less effective than maintaining a consistent dosage of ICS-LABA [51]. Stepping down from daily low-dose inhaled corticosteroids (ICS) along with beta-2 agonists (SABA) to only using ICS-formoterol as needed offers similar or even better protection against severe episodes of asthma and the requirement for emergency medical treatment. When compared to the daily use of low-dose ICS plus as needed SABA, this approach significantly reduces the average daily ICS dose while maintaining

similar control of symptoms and function of the lungs [4, 52].

#### **Recommended dosage for ICS in adults, adolescents and children with asthma according to GINA guidelines 2023**

##### ***Inhaled corticosteroid dose range for adults and adolescents (12 year and over)***

According to the GINA guidelines 2023, the recommended dosages for inhaled corticosteroids (ICS) in adults with asthma vary based on the severity of asthma and the specific treatment approach [4,23]. For adults with mild asthma, maintenance-and-reliever therapy (MART) with low-dose ICS/formoterol (160/4.5 µg for BUD/FOR or 100/6 µg) is recommended. It is crucial not to exceed the maximum daily dose of formoterol when using the MART approach. For patients with moderate-to-severe asthma, the preferred regimen is combination ICS/formoterol [2,25]. The maximum recommended daily dose of formoterol for patients 12 years and older is a total of 54 µg, including doses used for maintenance [4]. These dosages aim to optimize asthma control and reduce the risk of exacerbations while considering individual patient needs and treatment responses. Inhaled corticosteroid dose range for adults and adolescents (12 year and over) [4, 38-39].

**Table (2):** Inhaled corticosteroid dose range for adults and adolescents (12 year and over).

Inhaled Corticosteroid (ICS)	Total metered dose/ day (micrograms)		
	Low	Moderate	High
Budesonide	200-400	>400-800	>800
Ciclesonide	80-160	>160-320	>320
Mometasone furoate		200-400	>400
Fluticasone furoate	100		200
Fluticasone propionate	100-250	>250-500	>500
Beclomethasone dipropionate	100-200	> 200-400	>400

##### ***Inhaled corticosteroid dose range for children (6-11 years)***

In children aged 6 to 11 years with asthma, the recommended dosages of inhaled corticosteroids (ICS) vary based on severity. The dosages range from 80 to 320 micrograms per day, depending on whether it is a low, moderate, or high dose, administered as a single dose or in divided doses [4]. For children under 5 years old, the maximum recommended dose is 400 mcg/day, and for

those aged 5 to under 12 years, it is 800 mcg/day; doses exceeding 800 mcg/day are not licensed due to potential adverse effects [2]. It is crucial to avoid using short-acting beta-2 agonists (SABA) alone in children over 5 years old and prioritize ICS-containing therapy to reduce the risk of severe exacerbations. Inhaled corticosteroid dose range for children (6-11 years) See Table 3 [4].

**Table (3):** Inhaled corticosteroid dose range for children (6-11 years).

Inhaled Corticosteroid (ICS)	Total metered dose/ day (micrograms)		
	Low	Moderate	High
Budesonide	100-200	>200-400	>400
Ciclesonide	80	>80-160	>160
Mometasone furoate		100	200
Fluticasone furoate	50		n.a.
Fluticasone propionate	50-100	>100-200	>200
Beclomethasone dipropionate	50-100	>100-200	>200

### Consideration of pharmacogenomics used in asthma

The fields of genomics and pharmacogenomics offer the potential to enhance asthma control and reduce future risks associated with the condition [53]. Pharmacogenomics plays a crucial role in customizing asthma treatment by identifying genetic variations that influence responses to medications, optimizing medication choice, and dosages [53-54]. This personalized approach, combined with ongoing research in pharmacogenomics, aims to improve treatment outcomes while minimizing side effects [55]. Factors like age, comorbidities, environmental exposures, and other medications also impact asthma therapy complexity. Integrating pharmacogenomic data with clinical information provides a comprehensive view of individual patient profiles, enabling tailored therapeutic strategies and advancing precision medicine in asthma care to enhance patient outcomes and quality of life [53-54].

### Cost-effectiveness in asthma treatments

Determining the most cost-effective asthma treatment involves a nuanced approach that considers short-term costs like medication acquisition and delivery devices, as well as long-term costs and benefits such as hospitalizations, work productivity loss, and quality of life improvements. Inhaled corticosteroids (ICS) are fundamental for long-term control due to reduced exacerbations, with their initial cost balanced by long-term benefits. Long-acting beta agonists (LABA) as add-on therapy and combination therapies like ICS and LABA in a single inhaler vary in cost-effectiveness based on asthma severity and adherence [56]. For severe cases, biological therapies such as omalizumab can be highly effective despite their significant initial cost, showing potential

cost-effectiveness in specific patient groups with reduced hospitalizations and improved quality of life [57]. Individualized assessment by healthcare professionals is essential to consider both clinical effectiveness and cost-effectiveness in personalized asthma treatment plans, factoring in variables like asthma severity, medication response, and insurance coverage [58].

### Global availability of asthma medications

Globally, the prevalence of chronic respiratory illnesses is rising, with low- and middle-income countries (LMICs) experiencing the highest rates of disease-related mortality and morbidity [59]. An estimated 174 million people worldwide suffer from obstructive respiratory diseases like asthma, and 358 million from COPD [60]. Several studies have looked at the cost and accessibility of necessary drugs for the treatment of asthma and COPD in low-income countries settings, but these studies have typically only looked at a smaller number of pharmacies in rural as well as urban areas. With an aim of 80% availability of affordable medical supplies as well as vital medications to treat noncommunicable conditions, the WHO states that access to essential medications for noncommunicable conditions has been deemed a health care priority. The WHO lists the following drugs as essential necessities for a basic health system: beclomethasone, budesonide, budesonide/formoterol, ipratropium bromide and salbutamol aerosolized therapy, and epinephrine injection [61]. In a study, Trishul Siddharthan et. al, and others they surveyed 63 pharmacies in Nepal (95.2% private), 104 pharmacies in Peru (94.2% private) and 53 pharmacies in Uganda (98.1% private). During the period spanning 2017 to 2019, researchers engaged with both private and public pharmacies situated within the

specified regions of the global Excellence in COPD outcomes study sites, which included Bhaktapur, Nepal, Lima, Peru, Nakaseke and Uganda. The purpose was to evaluate the pricing and availability of medications for the management of asthma and COPD [60].

#### ***Availability of short-acting muscarinic and beta antagonists***

Among the three places (93.7% Nepal, 86.5% Peru, and 79.2% Uganda), salbutamol (WHO-EML) monotherapy in any composition was the most widely accessible respiratory drug. All three of the research places combined had 65.5% of pharmacies selling salbutamol monotherapy inhalers (87.3% in Nepal, 69.2% in Peru, and 32.1% in Uganda). Salbutamol monotherapy inhalers were not significantly more readily available in private pharmacies in Nepal (88.3%) than in public pharmacies (66.6%) ( $p = 0.22$ ). But at 34.1% pharmacies in all three study sites 82.5% in Nepal and 22.1% in Peru ipratropium bromide inhalers were less common than salbutamol ( $p < 0.05$ ). In Nepal, there was uniform availability of ipratropium bromide inhalers across all public pharmacies, with no discernible differences noted [60].

#### ***Availability of oral corticosteroids***

Oral corticosteroids (OCS) are stocked by the majority of pharmacies across all three locations, with availability rates of 71.4% in Nepal, 87.5% in Peru, and 100% in Uganda. Generic forms of OCS are also widely accessible. Prednisone was found to be widely available in most pharmacies in Uganda (88.7%), while dexamethasone was prevalent in the majority (98.1%). In Peru, prednisone and dexamethasone were also readily accessible, with availability rates of 86.5% and 78.9%, respectively. OCS was present in half (50.0%) of Peru's public pharmacies compared to 89.8% of its private pharmacies ( $p = 0.05$ ). In Nepal, OCS was present in every public pharmacy, while it was present in 70.0% of private pharmacies ( $p = 0.283$ ). OCS was carried by every public and private pharmacy in Uganda that was surveyed [60].

#### ***Availability of inhaled corticosteroids***

In Nepal (22.2% and 12.7%, and Peru (33.7% and 5.8%, respectively), beclomethasone (WHO-EML) and fluticasone were mainly unavailable. In Nepal, the inhaler for budesonide (WHO-EML) monotherapy was stocked in 41.3% of pharmacies, making

it the most widely accessible ICS. There were no ICS available in Uganda, and there were no budesonide data available for Peru. In Peru, public pharmacies (83.3%) had ICS more frequently than private pharmacies (30.6%) ( $p = 0.05$ ). Nepal also possessed the best combination therapy formulations (ICS+LABA, ICS+LAMA, ICS+SABA) [60].

#### ***Availability of long-acting beta agonists***

In Nepal, only 30.3% of pharmacies carried salmeterol, the medication used in LABA monotherapy. In Nepal, the bulk of public pharmacies (66.6%) carried salmeterol, while 28.3% of private pharmacies carried salmeterol inhalers ( $p = 0.17$ ). In contrast to Peru (6.7%, 7 total pharmacies with at least one), Nepal (87.3%, 55 total pharmacies with at least one combination) had a greater availability of ICS + LABA combination therapies. LABA therapy was not available in any of the Ugandan pharmacies surveyed. In Nepal, at least one ICS + LABA combination therapy was stocked in 88.3% of private pharmacies and 66.6% of public pharmacies, respectively ( $p = 0.22$ ). In Peru, the percentage of private pharmacies that carried ICS + LABA inhalers was 7.1%; public pharmacies did not carry the medication ( $p = 0.50$ ) [60].

#### ***Availability of long-acting muscarinic agonists***

Only Nepal (77.8%) had access to tiotropium monotherapy (WHO-EML). In Nepal, 66.6% of public pharmacies and 78.3% of private pharmacies carried tiotropium monotherapy ( $p = 0.60$ ). In Nepal, 14.3% of pharmacies carried the combination therapy of formoterol + tiotropium (LABA + LAMA, WHO-EML). In Nepal, 100% of public pharmacies and 13.3% of private pharmacies reported carrying LABA+LAMA inhalers ( $p=0.05$ ). In Nepal, the only LAMA formulations available were generic ones [60].

#### ***Side effects***

Possible local side effects from corticosteroid inhalation are, cough reflex, oesophageal-opharyngeal candidiasis, perioral dermatitis, a hoarse voice, having a dry mouth and a thirst, bad breath, or halitosis, an elevated risk, particularly in adults of tuberculosis, an atypical mycobacterial infection and pneumonia. Possible systemic side effects of inhaled corticosteroids encompass hindrance to linear growth (diminished growth rate leading to shorter

final stature), adrenal insufficiency or crisis as a result of suppression of the hypothalamic-pituitary-adrenal axis, implications for bone health such as osteoporosis and susceptibility to bone fractures, effects on immune function, and ocular complications including the development of cataracts and glaucoma. Additionally, there might be impairment in glycemic control [62]. These side effects depend on the type and dosage of ICS used along with how it is administered (e.g., dry powder inhalation (DPI) or metered-dose inhalation (MDI)).

### **Linear growth**

Despite the common saying that "being short never caused anyone harm" and the acknowledged ability of inhaled corticosteroids (ICSs) to manage a potentially life-threatening condition, parents' primary worries regarding these medications understandably revolve around the potential impact on their child's growth [63].

Systemically absorbed corticosteroids can influence linear growth through various mechanisms, including the suppression of growth hormone, down-regulation of growth hormone receptors, inhibition of insulin-like growth factor-1, and suppression of collagen synthesis at the epiphyseal growth plate. According to a Cochrane review conducted in 2014, the continual use of inhaled corticosteroids (ICSs) at low to medium daily doses is linked to an average reduction of 0.48 cm/year in linear growth velocity and a 0.61 cm variance in height from baseline over a one-year treatment period in children suffering from mild to moderate persistent asthma [65].

### **Suppression of the hypothalamic-pituitary-adrenal system**

High-dose corticosteroids from external sources can suppress adrenal function through negative feedback mechanisms. This suppression may lead to adrenal insufficiency, which can be overlooked until the body faces additional stress or a reduction in asthma treatment [63]. Previously considered rare, adrenal crises due to inhaled corticosteroid (ICS) use have been reported. Symptoms include fatigue, vomiting, and joint pain, progressing to hypotension and hypoglycaemia if untreated. Risk factors include prolonged use and high doses of ICSs, but even lower doses may cause problems.

Co-administration of medications enhancing steroid effects or additional steroid prescriptions heightens the risk. Evaluation for adrenal suppression, preferably by a paediatric endocrinologist using dynamic testing, is crucial for symptomatic and high-risk patients [66]. Management should involve collaboration between paediatric endocrinologists and asthma specialists, emphasizing patient and family education for early recognition and implementation of a rescue plan [64].

### **Effects on bone health**

Systemic glucocorticosteroid use can affect bone health, but studies haven't consistently linked inhaled corticosteroids (ICSs) with fractures or reduced bone density [67]. Recent research found no significant association between ICS use and fractures in asthma patients. However, systemic corticosteroid use was linked to a higher fracture risk. Clinicians should remain cautious, especially with additional risk factors for reduced bone density. Nutritional interventions ensuring sufficient vitamin D and calcium intake are crucial, and monitoring vitamin D levels in asthmatic children is advised [68,69]. Weight-bearing exercises are encouraged, but routine bone density screening isn't recommended for children using ICSs without major risk factors [64].

### **Complications related to the eyes (cataract and glaucoma)**

Because systemic steroids increase the risk of developing cataracts and glaucoma, researchers have looked into whether inhaled steroid therapy has similar effects on the eyes [70]. The CAMP study provided reassurance regarding cataract formation, as only one child out of 311 who received budesonide had a tiny posterior subcapsular cataract [71]. Similarly, there hasn't been an observed increase in glaucoma among children prescribed inhaled corticosteroids [64].

Other side effects including oropharyngeal candidiasis, which occurs in 5-25% of patients and is characterized by a burning sensation in the mouth and whitish rashes on mucous membranes. The risk of candidiasis is directly related to the dose and frequency of inhaled steroid use. Prevention strategies include rinsing the mouth after each inhalation, using a spacer or powder inhaler, and reducing the dose and frequency of steroid

administration during asthma remission [72, 61]. Another potential side effect is dysphonia, observed in 30-58% of patients, particularly those whose professions involve heavy voice use. This condition is attributed to steroid myopathy of the laryngeal muscles due to drug deposition [74]. Treatment options include switching to powder inhalers and decreasing the steroid dose. Irritation of the upper respiratory tract, characterized by cough and bronchospasm, can result from propellants in metered-dose inhalers (MDIS). Prevention methods include using SABA before corticosteroid inhalation, employing a spacer, and switching to powder inhalers [62, 74].

The consumption of inhaled corticosteroids is linked to a notable 34% rise in the chances of risk of incident diabetes, which is defined as the start of anti-diabetic medications, in a large group of COPD and asthma patients [75]. These medicines are often used in treating asthma or COPD, and patients are sometimes given high doses, equivalent to 1000µg of fluticasone daily with a 64% increase the chances of risk [76]. Furthermore, a study conducted by David B. Price and others they discovered that inhaled corticosteroids elevates the chances of developing risk to insulin therapy in patients already receiving oral hypoglycaemic agents for diabetes by 34%, and higher doses increased this risk of chances by 54% [77].

To manage systemic side effects of inhaled corticosteroids (ICS) in asthma patients, it's advised to prescribe the lowest effective ICS dose to maintain asthma control while minimizing adverse effects. Regular monitoring for signs of systemic side effects, such as cataracts, glaucoma, osteoporosis, and pneumonia, is crucial. Treatment plans should be tailored to each patient's needs, considering comorbidities and age-related factors that may impact systemic side effect risk. When systemic side effects are significant, alternative asthma medications or treatment approaches may be considered, particularly for elderly patients. Educational programs aimed at increasing awareness of ICS benefits and risks can enhance their appropriate use. Implementing these management strategies can optimize asthma treatment with ICS in elderly patients while mitigating systemic side effect risks.

## CONCLUSION

This review emphasizes the need for a comprehensive asthma management approach, integrating pharmacology, genetics, and improved healthcare delivery. This review highlights the historical evolution of asthma, from the use of smoke inhalation to modern inhalers, and the use of ICS and beta-2 adrenergic receptor agonists, addressing cost and medication accessibility. It emphasizes the potential of pharmacogenomics in customizing treatment based on genetic variations, while also addressing ICS side effects and proposing risk mitigation strategies. Adopting a holistic approach, the strategy aims to improve asthma control, reduce exacerbations, and elevate global patient outcomes. Integration of pharmacogenomic and clinical data enables tailored therapeutic approaches, advancing precision medicine in asthma care and enhancing patient quality of life. The review emphasizes delayed specialist referrals for complex asthma cases and provides revised treatment guidelines across severity levels, stressing tailored considerations in resource limited settings. Ultimately, it promotes for global asthma care challenges.

### **Ethics approval and consent to participate:**

N/A (This study has no human or animal participants; therefore, no consent was required)

**Consent for publication:** We declare that all authors have read and approved the paper. The paper has not been published previously, nor is it considered by any other journal.

**Availability of data and materials:** All data generated for this study are included in the article.

**Author's contribution:** **Shaili Dongare:** conceptualization, data curation, writing - original draft, writing - review & editing, visualization, validation. **Karishma Rathi:** ideation, visualization, validation, supervision, writing - review & editing, writing - original draft. **Gulshan Rathi:** Reviewer, writing - review & editing, visualization, validation

**Competing interest:** The authors report no conflicts of interest in this manuscript.

**Funding:** Any specific funding did not support this study.

**Acknowledgments:** None.

## REFERENCES

- 1] Aziz DA, Sajjad MA, Asad A. Global Initiative for Asthma (GINA) guideline: achieving optimal asthma control in children aged 6-11 years. *Monaldi Archives for Chest Disease*. 2023 Sep; 7; 2532 (5264): 2701. DOI: 10.4081/monaldi.2023.2701
- 2] Levy ML, Bacharier LB, Bateman E, Boulet LP, Brightling C, Buhl R, Brusselle G, Cruz AA, Drazen JM, Duijts L, Fleming L. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. *npj Primary Care Respiratory Medicine*. 2023 Feb 8; 33(1): 7. DOI: 10.1038/s41533-023-00330-1
- 3] Reddel HK, Bateman ED, Becker A, Boulet LP, Cruz AA, Drazen JM, Haahtela T, Hurd SS, Inoue H, de Jongste JC, Lemanske RF Jr, Levy ML, O'Byrne PM, Paggiaro P, Pedersen SE, Pizzichini E, Soto-Quiroz M, Szeffler SJ, Wong GW, FitzGerald JM. A summary of the new GINA strategy: a roadmap to asthma control. *Eur Respir J*. 2015 Sep 23; 46(3): 622-39. DOI: 10.1183/13993003.00853-2015.
- 4] Global initiative for asthma. Global strategy for asthma management and prevention, GINA Main Report. Updated 2023 July 10. <https://ginasthma.org/2023-gina-main-report/>
- 5] Capriotti DT, Dawn N, Ciocco T. Update on Asthma Management: the 2022 GINA Report. *Clinical Advisor*. 2023 Feb 24; DOI: <http://dx.doi.org/10.1002/alr.21609>.
- 6] Licari A, Marseglia G, Tosca MA, Ciprandi G. Asthma control in children and adolescents: a study in clinical practice. *Journal of Asthma*. 2020 Jun 2; 57(6): 645-7. DOI: 10.1080/02770903.2019.1594889.
- 7] Sakula A. Henry Hyde Salter (1823-71): a biographical sketch. *Thorax*. 1985 December; 40(12): 887. DOI: 10.1136/thx.40.12.887.
- 8] Holgate ST. A brief history of asthma and its mechanisms to modern concepts of disease pathogenesis. *Allergy, asthma & immunology research*. 2010 July; 2(3): 165-71. DOI: 10.4168/air.2010.2.3.165.
- 9] Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, Boushey HA, Calhoun WJ, Castro M, Cherniack RM, Craig T. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. *New England Journal of Medicine*. 2010 Oct 28; 363(18): 1715-26. DOI: 10.1056/NEJMoa1008770.
- 10] Chu EK, Drazen JM. Asthma: one hundred years of treatment and onward. *American journal of respiratory and critical care medicine*. 2005 Jun 1; 171(11): 1202-1208. DOI: 10.1164/rccm.200502-257OE.
- 11] Papi A, Blasi F, Canonica GW, Morandi L, Richeldi L, Rossi A. Treatment strategies for asthma: reshaping the concept of asthma management. *Allergy. Asthma & Clinical Immunology* 2020 Aug. 15; 16(75): 1-1. DOI: <https://doi.org/10.1186/s13223-020-00472-8>
- 12] Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? *European Respiratory Journal*. 2022 Nov 1; 60(5). DOI: 10.1183/13993003.02583-2021.
- 13] Schoettler N, Strek ME. Recent Advances in Severe Asthma: From Phenotypes to Personalized Medicine. *Chest*. 2020 March; 157(3): 516-528. DOI: 10.1016/j.chest.2019.10.009.
- 14] Rutjes NW, Golebski K, Şahin H, Hashimoto S, Maitland-van der Zee AH, Vijverberg SJH. Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab. *Paediatr Drugs*. 2023 Nov. 2; 25(6): 677-693. DOI: 10.1007/s40272-023-00589-4.
- 15] Kim SH, Kim Y. Tailored Biologics Selection in Severe Asthma. *Tuberc Respir Dis*. 2024 Jan.; 87(1): 12-21. DOI: 10.4046/trd.2023.0103.
- 16] Majellano EC, Clark VL, Winter NA, Gibson PG, McDonald VM. Approaches to the assessment of severe asthma: barriers and strategies. *J Asthma Allergy*. 2019 Aug 23; 12: 235-251. DOI: 10.2147/JAA.S178927.
- 17] Alangari AA. Corticosteroids in the treatment of acute asthma. *Ann Thorac Med*. 2014 Oct; 9(4): 187-92. DOI: 10.4103/1817-1737.140120.

- 18] Sinyor B, Concepcion Perez L. Pathophysiology of Asthma. Updated 2023 Jun-24. In: StatPearls Publishing; 2024 Jan. <https://www.ncbi.nlm.nih.gov/books/NBK551579/>
- 19] Ye, Q., He, XO. & D'Urzo, A. A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma. *Pulm Ther* 3, 1–18 (2017). <https://doi.org/10.1007/s41030-017-0043-5>
- 20] Limberg MM, Weihrauch T, Gray N, Ernst N, Hartmann K, Raap U. Eosinophils, Basophils, and Neutrophils in Bullous Pemphigoid. *Biomolecules*. 2023 Jun 21; 13(7): 1019. DOI: 10.3390/biom13071019.
- 21] Hough KP, Curtiss ML, Blain TJ, Liu RM, Trevor J, Deshane JS, Thannickal VJ. Airway Remodeling in Asthma. *Front Med*. 2020 May 21; 7: 191. DOI: 10.3389/fmed.2020.00191.
- 22] Becker DE. Basic and clinical pharmacology of glucocorticosteroids. *Anesth Prog*. 2013 Spring; 60(1): 25-31; quiz 32. DOI: 10.2344/0003-3006-60.1.25.
- 23] Barnes PJ. Inhaled corticosteroids. *Pharmaceuticals*. 2010 March 8; 3(3): 514-40. DOI: <https://doi.org/10.3390/ph3030514>
- 24] Liang TZ, Chao JH. Inhaled Corticosteroids. Updated 2023 May 8. In: Treasure Island (FL): StatPearls Publishing; 2024 Jan-Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470556/>
- 25] Celik GE, Aydın O, Damadoglu E, Baççioğlu A, Kepil Özdemir S, Bavbek S, Ediger D, Öner Erkeköl F, Gemicioglu B, Işık SR, Kalyoncu AF, Karakaya G, Keren M, Mungan D, Stepwise Approach in Asthma Revisited 2023: Expert Panel Opinion of Turkish Guideline of Asthma Diagnosis and Management Group. *Thorac Res Pract*. 2023 Nov; 24(6): 309-324. DOI: 10.5152/ThoracResPract.2023.23035.
- 26] Lea S, Higham A, Beech A, Singh D. How inhaled corticosteroids target inflammation in COPD. *European Respiratory Review*. 2023 Dec 31; 32(170). DOI: 10.1183/16000617.0084-2023.
- 27] O'Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P. Asthma progression and mortality: the role of inhaled corticosteroids. *European Respiratory Journal*. 2019 Jul 1; 54(1). DOI: 10.1183/13993003.00491-2019
- 28] Lewis, B.W.; Ford, M.L.; Rogers, L.K.; Britt, R.D., Jr. Oxidative Stress Promotes Corticosteroid Insensitivity in Asthma and COPD. *Antioxidants* 2021, 10. DOI: <https://doi.org/10.3390/antiox10091335>
- 29] Zustakova M, Kratochvilova L, Slama P. Apoptosis of eosinophil granulocytes. *Biology*. 2020 Dec 10; 9(12): 457. DOI: 10.3390/biology9120457
- 30] Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. *Molecular and cellular endocrinology*. 2011 Mar 15; 335(1): 2-13. DOI: 10.1016/j.mce.2010.04.005
- 31] Tavares LP, Galvão I, Ferrero MR. Novel Immunomodulatory Therapies for Respiratory Pathologies. *Comprehensive Pharmacology*. 2022 Jun 9.554-94. DOI: 10.1016/B978-0-12-820472-6.00073-6.
- 32] Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. *Br J Pharmacol*. 2006 Jun; 148(3): 245-54. DOI: 10.1038/sj.bjp.0706736.
- 33] Greeley MA. Immunopathology of the Respiratory System. *Immunopathology in Toxicology and Drug Development*. 2017 Mar 29: 419–53. DOI: 10.1007/978-3-319-47385-78.
- 34] Billington CK, Penn RB, Hall IP.  $\beta_2$  Agonists. *Handb Exp Pharmacol*. 2017; 237: 23-40. DOI: 10.1007/164\_2016\_64.
- 35] Hsu E, Bajaj T. Beta2-Agonists. Updated 2023 Jun 20. In: Treasure Island (FL): StatPearls Publishing; 2024 Jan-Available from: <https://www.ncbi.nlm.nih.gov/books/NBK542249/>
- 36] O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled combined budesonide–formoterol as needed in mild asthma. *The New England Journal of Medicine*. 2018 May 17; 378(20): 1865-76. DOI: 10.1056/NEJMoa1715274.
- 37] Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C et al. As-needed budesonide–formoterol



- versus maintenance budesonide in mild asthma. *The New England Journal of Medicine*. 2018 May 17; 378(20): 1877-87. DOI: 10.1056/NEJMoa1715275.
- 38] Dennis M Williams. Clinical Pharmacology of Corticosteroids. *Respiratory Care* June 2018; 63 (6) 655-670; DOI: <https://doi.org/10.4187/respcare.06314>
  - 39] Holst SS, Sabedin E, Sabedin E, Vermehren C. A Shift in Asthma Treatment According to New Guidelines: An Evaluation of Asthma Patients' Attitudes towards Treatment Change. *Int J Environ Res Public Health*. 2023 Feb 16; 20(4): 3453. DOI: 10.3390/ijerph20043453.
  - 40] Latorre M, Pistelli R, Carpagnano GE, Celi A, Puxeddu I, Scichilone N, Spanevello A, Canonica GW, Paggiaro P. Symptom versus exacerbation control: an evolution in GINA guidelines? *Ther Adv Respir Dis*. 2023 Jan-Dec; 17: 17534666231159261. DOI: 10.1177/17534666231159261.
  - 41] Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. *Am J Respir Crit Care Med*. 2022 Jan 1; 205(1): 17-35. DOI: 10.1164/rccm.202109-2205PP.
  - 42] Beaulieu MF, Lemiere C. Global Initiative for Asthma report: How will new recommendations affect practice in Canada. *CMAJ*. 2020 Apr 27; 192(17): E456-E458. DOI: 10.1503/cmaj.191445.
  - 43] DiMango E, Rogers L, Reibman J, et al. Risk factors for asthma exacerbation and treatment failure in adults and adolescents with well-controlled asthma during continuation and step-down therapy. *Annals of the American Thoracic Society* 2018 August; 15(8): 955-61. DOI: 10.1513/AnnalsATS.201711-886OC.
  - 44] Pelaia C, Calabrese C, Terracciano R, de Blasio F, Vatrella A, Pelaia G. Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness. *Therapeutic Advances in Respiratory Disease*. 2018; 12. DOI: 10.1177/1753466618810192.
  - 45] Kwon JW, Jung H, Kim SH, Chang YS, Cho YS, Nahm DH, Jang AS, Park JW, Yoon HJ, Cho SH, Cho YJ, Choi BW, Moon HB, Kim TB. High ACT score is not sufficient to reduce the risk of asthma exacerbations in asthma with low lung function. *Respiratory Medicine* 2019 Feb 12; 150: 38-44. DOI: 10.1016/j.rmed.2019.02.010.
  - 46] Rogers L, Sugar EA, Blake K, et al. Step-down therapy for asthma well controlled on inhaled corticosteroid and long-acting beta-agonist: A randomized clinical trial. *The Journal of Allergy and Clinical Immunology: In Practice* 2018 April; 6,(2): 633-43. DOI: <https://doi.org/10.1016/j.jaip.2017.07.030>
  - 47] Crossingham I, Turner S, Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. *Cochrane Database Systematic Reviews* 2021 May 04; 5: DOI: 10.1002/14651858.CD013518.pub2.
  - 48] Rogers L, Reibman J. Stepping down asthma treatment: how and when. *Curr Opin Pulm Med*. 2012 Jan; 18(1): 70-5. DOI: 10.1097/MCP.0b013e32834db017.
  - 49] Bleeker ER, Menzies-Gow AN, Price DB, Bourdin A, Sweet S, Martin AL, Alacqua M, Tran TN. Systematic literature review of systemic corticosteroid use for asthma management. *American journal of respiratory and critical care medicine*. 2020 Feb 1; 201(3): 276-93. DOI: <https://doi.org/10.1164/rccm.201904-0903SO>
  - 50] Martin RJ, Szeffler SJ, Chinchilli VM, Kraft M, Dolovich M, Boushey HA, Cherniack RM, Craig TJ, Drazen JM, Fagan JK, Fahy JV. Systemic effect comparisons of six inhaled corticosteroid preparations. *American journal of respiratory and critical care medicine*. 2002 May 15; 165(10): 1377-1383. DOI: 10.1164/rccm.2105013
  - 51] Syed SA, Sherwani NZ, Riaz B, Iqbal J, Chaudhry M, Abdullah M, Malik A. Short-Term Effect of Inhaled Salbutamol on Heart Rate in Healthy Volunteers.

- Cureus. 2021 Mar 3; 13(3). DOI: 10.7759/cureus.13672
- 52] Bloom CI, Ramsey H, Alter M, Lakhani S, Wong E, Hickman K, Elkin SL, Majeed A, El-Osta A. Qualitative study of practices and challenges of stepping down asthma medication in primary care across the UK. *Journal of Asthma and Allergy*. 2020 Oct 6; 13: 429-37. DOI: <https://doi.org/10.2147/JAA.S274943>
  - 53] Ferrante G, Fasola S, Malizia V, Licari A, Cilluffo G, Piacentini G, La Grutta S. Pharmacogenomics: A Step forward Precision Medicine in Childhood Asthma. *Genes*. 2022 Mar 28; 13(4): 599. DOI: 10.3390/genes13040599.
  - 54] García-Menaya JM, Cordobés-Durán C, García-Martín E, Agúndez JAG. Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy. *Front Pharmacol*. 2019 May 21; 10: 520. DOI: 10.3389/fphar.2019.00520.
  - 55] Edris A, Callier E, Lahousse L. Precision medicine from a citizen perspective: a survey of public attitudes towards pharmacogenomics in Flanders. *BMC Medical Genomics*. 2022 Sep 12; 15(Suppl 3): 193. DOI: <https://doi.org/10.1186/s12920-022-01308-7>
  - 56] Padilla-Galo A, García-Ruiz AJ, Levy Abitbol RC, Oliveira C, Rivas-Ruiz F, García-Agua Soler N, Pérez Morales M, Valencia Azcona B, Tortajada-Goitia B, Moya-Carmona I, Levy-Naon A. Real-life cost-effectiveness of benralizumab in patients with severe asthma. *Respiratory research*. 2021 May 27; 22(1): 163. DOI: <https://doi.org/10.1186/s12931-021-01758-0>
  - 57] Hanania NA, Niven R, Chanez P, Antoine D, Pfister P, Garcia Conde L, Jaumont X. Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma. *World Allergy Organ J*. 2022 Sep 25; 15(10): 100695. DOI: 10.1016/j.waojou.2022.100695.
  - 58] Menzella F, Galeone C, Ghidoni G, Ruggiero P, D'Amato M, Fontana M, Facciolo N. The pharmacoeconomics of the state-of-the-art drug treatments for asthma: a systematic review. *Multidiscip Respir Med*. 2021 Aug 2; 16(1): 787. DOI: 10.4081/mrm.2021.787.
  - 59] Soriano JB, Abajobir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet Respiratory Medicine*. 2017; 5(9): 691–706. DOI: [https://doi.org/10.1016/S2213-2600\(17\)30293](https://doi.org/10.1016/S2213-2600(17)30293)
  - 60] Siddharthan T, Robertson NM, Rykiel NA, Underhill LJ, Rahman N, Kafle S, Mohan S, Padalkar R, McKeown S, Flores-Flores O, Quaderi SA. Availability, affordability and access to essential medications for asthma and chronic obstructive pulmonary disease in three low-and middle-income country settings. *PLOS Global Public Health*. 2022 Dec 16; 2(12): e0001309. DOI: <https://doi.org/10.1371/journal.pgph.0001309>.
  - 61] Khanal S, Veerman L, Ewen M, Nissen L, Hollingworth S. Availability, price, and affordability of essential medicines to manage noncommunicable diseases: A national survey from Nepal. *The Journal of Health Care Organization, Provision, and Financing*. 2019; 56: 0046958019887572. DOI: <https://doi.org/10.1177/0046958019887572>
  - 62] Jamshidovich as. Effect inhaled glucocorticoids in chronic obstructive pulmonary disease and bronchial asthma. *Tadqiqotlar*. 2024 feb 1; 31(1): 171-80.
  - 63] Wolfgram PM, Allen DB. Effects of Inhaled Corticosteroids on Growth, Bone Metabolism, and Adrenal Function. *Adv Pediatr*. 2017; 64(1): 331–45. DOI: <http://dx.doi.org/10.1016/j.yapd.2017.03.006>
  - 64] Gidaris D, Stabouli S, Bush A. Beware the inhaled steroids or corticophobia. *Swiss Medical Weekly*. 2021 Feb 6; 151.0506 DOI: <https://doi.org/10.4414/smw.2021.20450>.
  - 65] Zhang L, Prietsch SO, Ducharme FM. Inhaled corticosteroids in children with persistent asthma: effects on growth. *Cochrane Database Syst Rev*. 2014; 7(4): CD009471. DOI: <http://dx.doi.org/10.1002/ebch.1988>.
  - 66] Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey

- of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. *Arch Dis Child*. 2002; 87(6): 457–61. DOI: <http://dx.doi.org/10.1136/adc.87.6.457>.
- 67] Tse SM, Kelly HW, Litonjua AA, Van Natta ML, Weiss ST, Tantisira KG; Childhood Asthma Management Program Research Group. Corticosteroid use and bone mineral accretion in children with asthma: effect modification by vitamin D. *J Allergy Clin Immunol*. 2012; 130(1): 53–60.e4. DOI: <http://dx.doi.org/10.1016/j.jaci.2012.04.005>.
- 68] Hall SC, Agrawal DK. Vitamin D and Bronchial Asthma: An Overview of Data From the Past 5 Years. *Clin Ther*. 2017; 39(5): 917–29. DOI: <http://dx.doi.org/10.1016/j.clinthera.2017.04.002>.
- 69] Liu J, Dong YQ, Yin J, Yao J, Shen J, Sheng GJ, et al. Meta-analysis of vitamin D and lung function in patients with asthma. *Respir Res*. 2019; 20(1): 161. DOI: <http://dx.doi.org/10.1186/s12931-019-1072-4>.
- 70] Nootheti S, Bielory L. Risk of cataracts and glaucoma with inhaled steroid use in children. *Compr Ophthalmol Update*. 2006; 7(1): 31–9.
- 71] Chang LS, Lee HC, Tsai YC, Shen LS, Li CL, Liu SF, et al. Decreased incidence of glaucoma in children with asthma using inhaled corticosteroid: a cohort study. *Oncotarget*. 2017; 8(62): 105463–71. DOI: <http://dx.doi.org/10.18632/oncotarget.22252>.
- 72] Pacheco-Quito EM, Jaramillo J, Sarmiento-Ordonez J, Cuenca-Leon K. Drugs Prescribed for Asthma and Their Adverse Effects on Dental Health. *Dentistry Journal*. 2023 Apr 26; 11(5): 113. <https://doi.org/10.3390/dj11050113>
- 73] Galvan CA, Guarderas JC. Practical considerations for dysphonia caused by inhaled corticosteroids. *Mayo Clin Proc*. 2012 Sep; 87(9): 901-4. DOI: 10.1016/j.mayocp.2012.06.022.
- 74] Souza AM, Duprat Ade C, Costa RC, Pimenta Jde O, Andrade FF, Silva FF. Use of inhaled versus oral steroids for acute dysphonia. *Braz J Otorhinolaryngol*. 2013 Mar-Apr; 79(2): 196-202. DOI: 10.5935/1808-8694.20130035.
- 75] See KC. Impact of inhaled and intranasal corticosteroids on glucose metabolism and diabetes mellitus: A mini review. *World J Diabetes* 2023; 14(8): 1202-1211. DOI: [10.4239/wjd.v14.i8.1202](https://doi.org/10.4239/wjd.v14.i8.1202)
- 76] Stallberg B, Janson C, Lisspers K, Johansson G, Gutzwiller FS, Mezzi K, Bjerregaard BK, Kejs AMT, Jorgensen L, Larsson K. Inhaled corticosteroids and the risk of type 2 diabetes among Swedish COPD patients. *NPJ Prim Care Respir Med*. 2020 Oct 20; 30(1): 47. DOI: 10.1038/s41533-020-00207-7.
- 77] Price DB, Voorham J, Brusselle G, Clemens A, Kostikas K, Stephens JW, Park HY, Roche N, Fogel R. Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. *NPJ primary care respiratory medicine*. 2019 Oct 28; 29(1): 38. DOI: 10.1038/s41533-019-0150-x